Abstract Details

Title "Responder or Non-Responder, That Is the Question." Was the Responder Definition Used in the Dalfampridine Extended Release Studies Clinically Meaningful?

Topic MS and Related Diseases

Presentation(s) (-)

Poster/Presentation
Number 202

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Jeremy C. Hobart, MD (Derriford Hospital)	Dr. Hobart has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Hobart has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi.
	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��